Understanding GLP-1 Agonists and China's Growing Need
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a transformative class of medications originally developed for managing type 2 diabetes mellitus (T2D). These drugs mimic the GLP-1 hormone, which is naturally released in the gut after eating, to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. The result is improved blood glucose control and substantial weight loss, addressing two major challenges in T2D treatment.
In China, the urgency is palpable. With approximately 148 million adults living with diabetes in 2024—the highest number globally—the country faces an epidemic fueled by rapid urbanization, dietary shifts, and aging populations. Prevalence rates have climbed to 11.9% among adults aged 20-79, projecting further increases without intervention. Central obesity, a hallmark in many Chinese patients, exacerbates cardiovascular risks, making dual-action therapies particularly valuable.
Traditional treatments often fall short in achieving sustained glycemic control (HbA1c below 7%) while promoting weight loss. Enter mazdutide, a homegrown innovation poised to change that narrative.
Mazdutide: A Dual-Receptor Powerhouse from Innovent Biologics
Mazdutide (信尔美®), developed by Suzhou-based Innovent Biologics in partnership with Eli Lilly, is the world's first approved glucagon receptor (GCGR)/GLP-1 receptor (GLP-1R) dual agonist. Administered as a once-weekly subcutaneous injection, it combines GLP-1's glucose-lowering and appetite-suppressing effects with glucagon's energy-expending properties. This synergy targets both hyperglycemia and excess adiposity more effectively than single-agonist therapies.
Approved by China's National Medical Products Administration (NMPA) in June 2025 for weight management in adults with obesity or overweight (with at least one weight-related comorbidity) and in September 2025 for T2D glycemic control alongside diet and exercise, mazdutide marks a milestone for domestic innovation. Its path to prominence culminated in two phase 3 trials published back-to-back in the prestigious Nature journal on December 17, 2025—the first such achievement for a Chinese metabolic drug.
Behind this success are collaborations with leading Chinese academic institutions, including Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School and Shandong Provincial Hospital, underscoring the pivotal role of university-led research in translating lab discoveries to clinic.
DREAMS-1 Trial: Monotherapy Triumph Over Placebo
The DREAMS-1 trial (NCT05628311) evaluated mazdutide as monotherapy in 320 Chinese adults with T2D inadequately controlled by diet and exercise alone. Participants averaged 8.24% baseline HbA1c, 28.2 kg/m² BMI, and 1.9 years diabetes duration—reflecting early-stage patients common in China.
Randomized 1:1:1 to 4 mg, 6 mg mazdutide, or placebo weekly for 24 weeks (followed by extension), the primary endpoint was HbA1c change at week 24. Results were striking: mazdutide 4 mg yielded -1.57% HbA1c reduction, 6 mg -2.15%, versus -0.14% for placebo (treatment differences -1.43% and -2.02%, both p<0.0001). Weight loss reached -5.61% (4 mg) and -7.81% (6 mg) versus -1.26% placebo.
- 63.6% (4 mg) and 76.5% (6 mg) achieved HbA1c <7.0% vs 12.9% placebo.
- 57.1% (4 mg) and 70.6% (6 mg) hit ≥5% weight loss vs 10.6% placebo.
- Composite (HbA1c <7.0% + ≥5% weight loss): 48.4% and 60.0% vs 3.2%.
These outcomes highlight mazdutide's potential as a first-line therapy, especially valuable for researchers exploring early intervention strategies in Chinese cohorts.
DREAMS-2: Superiority Against Dulaglutide Standard
Building on monotherapy success, DREAMS-2 (NCT05606913) tested mazdutide 4 mg and 6 mg added to oral antidiabetics versus dulaglutide 1.5 mg (a established GLP-1RA) in 731 Chinese T2D patients. At weeks 24-28, 6 mg mazdutide achieved -1.66% to -2.02% HbA1c reductions, outperforming dulaglutide, with weight losses up to -8.53%.
Beyond glycemia, benefits spanned fasting plasma glucose, systolic blood pressure, lipids (triglycerides, total cholesterol), and liver enzymes—key for China's metabolic syndrome profile. No severe hypoglycemia occurred, reinforcing its safety in combination regimens.
Lead investigators from top universities like Nanjing University emphasize how these trials validate dual-agonism tailored to Asian phenotypes, where visceral fat predominates.Explore research positions advancing such innovations at AcademicJobs.com/research-jobs.
Safety Profile: Manageable and Familiar
Consistent with GLP-1RAs, most adverse events were mild-to-moderate gastrointestinal: diarrhea, nausea, decreased appetite. Incidence peaked early and waned; no new safety signals emerged. Discontinuation rates were low, comparable to comparators, affirming mazdutide's tolerability in Chinese patients.
Long-term data from extensions suggest sustained benefits without heightened risks, crucial for chronic T2D management.
Implications for China's Diabetes Landscape
With 148 million diabetics, therapies like mazdutide could alleviate a Rmb1 trillion annual burden. Superior weight loss addresses central obesity, reducing cardiovascular events—a top killer. As a 'China Solution,' it leverages local data for optimized dosing, potentially lowering costs versus imports like semaglutide.
In higher education, this fuels China-focused academic opportunities, from clinical trials to pharmacogenomics research.
Read the DREAMS-1 study in Nature | DREAMS-2 full paperGlobal Ripples and Academic Prestige
Nature's endorsement elevates Chinese biotech, challenging Western dominance in GLP-1 innovation. Dozens of domestic candidates pipeline, but mazdutide leads with proven phase 3 data. Universities like those in Nanjing and Jinan gain international acclaim, attracting global talent.
For aspiring researchers, this signals booming demand in endocrinology; check faculty roles or postdoc positions.
Market Dynamics and Accessibility
China's GLP-1 market eyes $14B by 2030, with mazdutide capturing share post-semaglutide patent expiry in 2026. Early sales project strong uptake, aided by NMPA fast-track.
Inclusion in national reimbursement could democratize access, aligning with Healthy China 2030.
Future Horizons: Beyond Diabetes
Ongoing trials explore obesity, MASH, HFpEF, OSA, even adolescents. DREAMS-3 beat semaglutide; GLORY series advance weight loss data. Dual-agonism may redefine metabolic therapy globally.
Chinese universities drive this, offering career advice for researchers.
Stakeholder Perspectives and Next Steps
Clinicians praise tailored efficacy; patients report better adherence. Dr. Lei Qian of Innovent: 'Expected to inform global guidelines.' For academics, it's a call to collaborate on real-world evidence.
Visit RateMyProfessor for insights on top endocrinology faculty, or higher-ed-jobs for openings. Explore career advice to join this revolution.
